Next, we focus on the consistent and discrepant outcomes from two anti-VEGFR and two anti-VEGF pre-clinical obesity studies; along with other relevant evidence, we discuss the considerations for future anti-VEGFR/VEGF therapies for obesity treatment. The gene discussed is KDR; the disease is obesity due to melanocortin 4 receptor deficiency.